Skip to content

Study · Systematic review · 2026

10 results

Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks.

Carminati M, Tondello M, Concina A, Olgiati P, Zanardi R

International clinical psychopharmacology30 Jun 2025Cited by 4 (Europe PMC)

PMID40577093 (opens in a new tab)DOI10.1097/yic.0000000000000595 (opens in a new tab)PepBankPUB-40577093
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    A systematic review of 37 studies found that semaglutide was effective in various psychiatric populations.

    In plain wordsA review of studies found that semaglutide was effective in several groups of people with psychiatric conditions.

    Peptide
    Semaglutide
    Outcome
    Not applicableEffectiveness in psychiatric populations
    Study

    n: not reported in source

    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SEM is effective and well-tolerated in various psychiatric populations
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  2. 02HumanSystematic reviewSafety outcome

    A systematic review of 37 studies found that semaglutide was well tolerated in various psychiatric populations.

    In plain wordsA review of studies found that semaglutide was well tolerated in several groups of people with psychiatric conditions.

    Peptide
    Semaglutide
    Outcome
    Not applicableTolerability in psychiatric populations
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SEM is effective and well-tolerated in various psychiatric populations
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  3. 03HumanSystematic reviewEfficacy outcome

    In the systematic review, semaglutide was of great interest for binge eating disorder (BED) and acted on weight decrease.

    In plain wordsA review found that semaglutide reduced weight in people with binge eating disorder.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight decrease in binge eating disorder
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SEM showed to be of great interest in the treatment of BED, acting not only on weight decrease but also on cognitive symptoms linked to the disease.
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  4. 04HumanSystematic reviewEfficacy outcome

    In the systematic review, semaglutide acted on the cognitive symptoms linked to binge eating disorder (BED).

    In plain wordsA review found that semaglutide acted on thinking-related symptoms linked to binge eating disorder.

    Peptide
    Semaglutide
    Outcome
    Not applicableCognitive symptoms in binge eating disorder
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SEM showed to be of great interest in the treatment of BED, acting not only on weight decrease but also on cognitive symptoms linked to the disease.
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  5. 05HumanSystematic reviewEfficacy outcome

    The systematic review reported potential benefits of semaglutide in managing metabolic disturbances in psychotic disorders.

    In plain wordsA review reported possible benefits of semaglutide for metabolic problems in people with psychotic disorders.

    Peptide
    Semaglutide
    Outcome
    Not applicableMetabolic disturbances in psychotic disorders
    Study

    n: not reported in source

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    potential benefits in managing binge eating disorder (BED), metabolic disturbances in psychotic disorders, and alcohol use disorder
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  6. 06HumanSystematic reviewEfficacy outcome

    The systematic review reported preliminary findings of benefit from semaglutide in alcohol use disorder.

    In plain wordsA review reported early, preliminary findings of possible benefit from semaglutide in alcohol use disorder.

    Peptide
    Semaglutide
    Outcome
    Not applicableAlcohol use disorder
    Study

    n: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar findings, though preliminary, have been observed for the treatment of alcohol and substance use disorder.
    3 context sentences
    Summary · context
    potential benefits in managing binge eating disorder (BED), metabolic disturbances in psychotic disorders, and alcohol use disorder
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  7. 07HumanSystematic reviewEfficacy outcome

    The systematic review reported preliminary findings of benefit from semaglutide in substance use disorder.

    In plain wordsA review reported early, preliminary findings of possible benefit from semaglutide in substance use disorder.

    Peptide
    Semaglutide
    Outcome
    Not applicableSubstance use disorder
    Study

    n: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar findings, though preliminary, have been observed for the treatment of alcohol and substance use disorder.
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  8. 08HumanSystematic reviewSafety outcome

    The systematic review reported that semaglutide was linked to depressive symptoms.

    In plain wordsA review reported that semaglutide was linked to depressive symptoms.

    Peptide
    Semaglutide
    Outcome
    IncreaseDepressive symptoms
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    these drugs are also linked to depressive symptoms and suicidal ideation
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  9. 09HumanSystematic reviewSafety outcome

    The systematic review reported that semaglutide was linked to suicidal ideation.

    In plain wordsA review reported that semaglutide was linked to suicidal ideation.

    Peptide
    Semaglutide
    Outcome
    IncreaseSuicidal ideation
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    these drugs are also linked to depressive symptoms and suicidal ideation
    2 context sentences
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.
  10. 10HumanSystematic reviewEfficacy outcome

    In the systematic review, the use of semaglutide in mood disorders, in particular depression, was still controversial, with preliminary evidence of potential antidepressant effects.

    In plain wordsA review found that the evidence on semaglutide for depression and mood disorders is still unclear and preliminary.

    Peptide
    Semaglutide
    Outcome
    MixedDepression and mood disorders
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of SEM in mood disorders, in particular depression, is still controversial.
    3 context sentences
    Summary · context
    potential antidepressant effects, though this evidence is preliminary
    Summary · context
    A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria.
    Summary · context
    The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.